While Semaglutide is safe to use, it is not intended for use if you have any of the following: Personal or family history of medullary thyroid cancer Type-1 diabetes Multiple Endocrine Neoplasia Syndrome Type 2 Known allergy to Semaglutide Currently breastfeeding or have a plan to breastfeed Currently pregnant Please call our office at (540) 556-1061 for details and to determine if you are a good candidate for the use of Semaglutide for weight loss
Studies from the last few years have identified the role of gut microbiota in human brain health and disease [15,16,17,18,19]
correlation of hepatic necrosis, covalent binding and glutathione depletion in hamsters
This increases: hepatic fat oxidation energy expenditure triglyceride mobilization References: Habegger KM et al., Nature Medicine , 2010 Kim T et al., Cell Metabolism , 2018 Clinical Trial Evidence Obesity (Phase 2) Key outcomes: up to 24% body weight reduction majority of weight loss from fat mass Reference: Type 2 Diabetes Observed effects: HbA1c reduction improved glycemic control reduced insulin resistance Reference: Body Composition Effects Retatrutide appears to: reduce visceral adipose tissue reduce hepatic steatosis preserve lean mass when combined with resistance training Reference: Gastaldelli A et al., Diabetes , 2020 Neurological Research Context GLP-1 receptors are expressed in multiple brain regions including: hippocampus hypothalamus cortex These pathways may influence: neuroinflammation neuronal energy metabolism cognitive signaling Reference: Hlscher C, Nature Reviews Neuroscience , 2014 Cardiovascular and Renal Effects Incretin therapies have demonstrated: improved endothelial function reduced systemic inflammation lower cardiovascular risk markers Reference: Marso SP et al., NEJM , 2016 Safety and Tolerability Common adverse events in trials include: nausea vomiting diarrhea constipation These are generally dose-dependent and improve with titration
Energy & fatigue - reduces physical and mental fatigue, particularly in older adults and vegetarians
Indirect association shows abnormal copper content in the SN of PD patients [131], but evidence of cuproptosis-specific markers (e.g., lipoylated protein aggregation) is lacking
